265 related articles for article (PubMed ID: 15713979)
1. The role of p53 and anaplastic lymphoma kinase genes in the progression of cutaneous CD30(+) lymphoproliferative diseases.
Kapur S; Tiemann M; Menke MA; Schubert C; Parwaresch R
Indian J Med Res; 2005 Jan; 121(1):46-54. PubMed ID: 15713979
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders.
Benner MF; Jansen PM; Meijer CJ; Willemze R
Br J Dermatol; 2009 Jul; 161(1):121-7. PubMed ID: 19416236
[TBL] [Abstract][Full Text] [Related]
3. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
Kempf W; Kutzner H; Cozzio A; Sander CA; Pfaltz MC; Müller B; Pfaltz M
Br J Dermatol; 2008 Jun; 158(6):1280-7. PubMed ID: 18410414
[TBL] [Abstract][Full Text] [Related]
4. The t(2;5)-associated p80 NPM/ALK fusion protein in nodal and cutaneous CD30+ lymphoproliferative disorders.
Su LD; Schnitzer B; Ross CW; Vasef M; Mori S; Shiota M; Mason DY; Pulford K; Headington JT; Singleton TP
J Cutan Pathol; 1997 Nov; 24(10):597-603. PubMed ID: 9449486
[TBL] [Abstract][Full Text] [Related]
5. Absence of anaplastic lymphoma kinase (ALK) and Epstein-Barr virus gene products in primary cutaneous anaplastic large cell lymphoma and lymphomatoid papulosis.
Herbst H; Sander C; Tronnier M; Kutzner H; Hügel H; Kaudewitz P
Br J Dermatol; 1997 Nov; 137(5):680-6. PubMed ID: 9415224
[TBL] [Abstract][Full Text] [Related]
6. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin.
DeCoteau JF; Butmarc JR; Kinney MC; Kadin ME
Blood; 1996 Apr; 87(8):3437-41. PubMed ID: 8605362
[TBL] [Abstract][Full Text] [Related]
7. FOXP3 positive regulatory T-cells in cutaneous and systemic CD30 positive T-cell lymphoproliferations.
Gjerdrum LM; Woetmann A; Odum N; Hother C; Henrik-Nielsen R; Gniadecki R; Ralfkiaer E
Eur J Haematol; 2008 Jun; 80(6):483-9. PubMed ID: 18331599
[TBL] [Abstract][Full Text] [Related]
8. Fascin expression in CD30-positive cutaneous lymphoproliferative disorders.
Kempf W; Levi E; Kamarashev J; Kutzner H; Pfeifer W; Petrogiannis-Haliotis T; Burg G; Kadin ME
J Cutan Pathol; 2002 May; 29(5):295-300. PubMed ID: 12100631
[TBL] [Abstract][Full Text] [Related]
9. ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects--a review.
ten Berge RL; Oudejans JJ; Ossenkoppele GJ; Meijer CJ
J Pathol; 2003 May; 200(1):4-15. PubMed ID: 12692835
[TBL] [Abstract][Full Text] [Related]
10. Current management of primary cutaneous CD30+ T-cell lymphoproliferative disorders.
Kadin ME
Oncology (Williston Park); 2009 Nov; 23(13):1158-64. PubMed ID: 20043465
[TBL] [Abstract][Full Text] [Related]
11. Primary cutaneous CD30+ lymphoproliferative disorder--a 10-year follow-up. A case report and differential diagnosis.
Szpor J; Dyduch G; Gałazka K; Bahyrycz J; Stój A; Tomaszewska R
Pol J Pathol; 2009; 60(1):43-8. PubMed ID: 19670703
[TBL] [Abstract][Full Text] [Related]
12. Abnormal activator protein 1 transcription factor expression in CD30-positive cutaneous large-cell lymphomas.
Mao X; Orchard G; Russell-Jones R; Whittaker S
Br J Dermatol; 2007 Nov; 157(5):914-21. PubMed ID: 17725669
[TBL] [Abstract][Full Text] [Related]
13. Intralymphatic cutaneous anaplastic large cell lymphoma/lymphomatoid papulosis: expanding the spectrum of CD30-positive lymphoproliferative disorders.
Samols MA; Su A; Ra S; Cappel MA; Louissant A; Knudson RA; Ketterling RP; Said J; Binder S; Harris NL; Feldman AL; Kim J; Kim YH; Gratzinger D
Am J Surg Pathol; 2014 Sep; 38(9):1203-11. PubMed ID: 24805854
[TBL] [Abstract][Full Text] [Related]
14. Genomic Analysis of Cutaneous CD30-Positive Lymphoproliferative Disorders.
Abdulla FR; Zhang W; Wu X; Honda K; Qin H; Cho H; Querfeld C; Zain J; Rosen ST; Chan WC; Parekh V; Song JY
JID Innov; 2022 Jan; 2(1):100068. PubMed ID: 34977845
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma.
Eckerle S; Brune V; Döring C; Tiacci E; Bohle V; Sundström C; Kodet R; Paulli M; Falini B; Klapper W; Chaubert AB; Willenbrock K; Metzler D; Bräuninger A; Küppers R; Hansmann ML
Leukemia; 2009 Nov; 23(11):2129-38. PubMed ID: 19657361
[TBL] [Abstract][Full Text] [Related]
16. Fatal ALK-negative systemic anaplastic large cell lymphoma presenting with disseminated cutaneous dome-shaped papules and nodules.
Bird JE; Leitenberger JJ; Solomon A; Blauvelt A; Hopkins S
Dermatol Online J; 2012 May; 18(5):5. PubMed ID: 22630575
[TBL] [Abstract][Full Text] [Related]
17. Detection of clonal rearrangement of T-cell receptor genes in the diagnosis of primary cutaneous CD30 lymphoproliferative disorders.
Greisser J; Palmedo G; Sander C; Kutzner H; Kazakov DV; Roos M; Burg G; Kempf W
J Cutan Pathol; 2006 Nov; 33(11):711-5. PubMed ID: 17083688
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous CD30-positive lymphoproliferative disorders with CD8 expression: a clinicopathologic study of 21 cases.
Plaza JA; Feldman AL; Magro C
J Cutan Pathol; 2013 Feb; 40(2):236-47. PubMed ID: 23189966
[TBL] [Abstract][Full Text] [Related]
19. The significance of MUM1/IRF4 protein expression and IRF4 translocation of CD30(+) cutaneous T-cell lymphoproliferative disorders: a study of 53 cases.
Kiran T; Demirkesen C; Eker C; Kumusoglu H; Tuzuner N
Leuk Res; 2013 Apr; 37(4):396-400. PubMed ID: 23332472
[TBL] [Abstract][Full Text] [Related]
20. c-Jun expression and activation are restricted to CD30+ lymphoproliferative disorders.
Drakos E; Leventaki V; Schlette EJ; Jones D; Lin P; Medeiros LJ; Rassidakis GZ
Am J Surg Pathol; 2007 Mar; 31(3):447-53. PubMed ID: 17325487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
